Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

Phase 2 Data Demonstrate Potential of Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries

Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309